In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …

Context Various molecular mechanisms play a role in the development of resistance to
androgen deprivation therapy in castration-resistant prostate cancer (CRPC). Objective To …

Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR)
signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal …

Multiple mechanisms of resistance contribute to the inevitable progression of hormone-
sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved …

Despite the initial efficacy of androgen deprivation in prostate cancer, virtually all patients
progress to castration-resistant prostate cancer (CRPC). Androgen receptor (AR) signaling …

Prostate cancer therapy for locally advanced and metastatic diseases includes androgen
deprivation therapy (ADT). Second-generation antiandrogens have a role in castration …

Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (CRPC), a disease state now recognized to retain …

The FDA approvals of enzalutamide and abiraterone have rapidly changed the clinical
landscape of prostate cancer treatment. Both drugs were designed to further suppress …

Androgen deprivation therapy targeting the androgens/androgen receptor (AR) signaling
continues to be the mainstay treatment of advanced-stage prostate cancer. The use of …

Several mechanisms facilitate the progression of hormone-sensitive prostate cancer to
castration-resistant prostate cancer (CRPC). At present, the approved chemotherapies for …